NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vestis Corporation (NYSE: VSTS).Shareholders who purchased shares of VSTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/vestis-corporation-loss-submission-form/?id=156353&from=4 CLASS PERIOD: May 2, 2024 to M ...

NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156357&from=4 CLASS PERIOD: June 22, 2023 to ...

NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF).Shareholders who purchased shares of WOOF during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/petco-loss-submission-form/?id=156359&from=4 CLASS PERIOD: Januar ...

NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=156354&from=4 CLASS PERI ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Iovance Biotherapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, and highlights the potential for compensation without out-of-pocket costs through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Iovance securities between May 9, 2024, and May 8, 2025, may be eligible to join a class action lawsuit [1][2]. - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of its sales team and new Authorized Treatment Centers (ATCs), which resulted in higher costs and lower revenue due to patient drop-offs and delays in treatment initiation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting that many firms may not have the necessary experience or resources [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019, and has been recognized for its success in securities class action settlements [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of iRobot Corporation securities purchasers during the specified Class Period, indicating potential legal issues for the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between January 29, 2024, and March 11, 2025, and aims to address misleading statements made by iRobot regarding its financial stability and restructuring plans [1][5]. - The lawsuit claims that iRobot overstated the effectiveness of its Restructuring Plan following the termination of the Amazon Acquisition, leading to doubts about its ability to operate profitably as a standalone entity [5]. Group 2: Investor Information - Investors who purchased iRobot securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Red Cat Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 22, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Red Cat securities between March 18, 2022, and January 15, 2025, may be eligible for compensation through a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline [2][4]. - The lawsuit alleges that Red Cat made false and misleading statements regarding its production capacity and the value of its contracts, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Red Cat Holdings, Inc. securities between March 18, 2022, and January 15, 2025, of the July 22, 2025, deadline to become a lead plaintiff in a class action lawsuit due to alleged misleading statements by the company [1][4]. Group 1: Class Action Details - Investors who purchased Red Cat securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by July 22, 2025, to serve as lead plaintiff [2]. - The lawsuit claims that Red Cat made false and misleading statements regarding its production capacity and the value of its contracts, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly providing misleading information regarding its growth potential and operational capabilities during the class period from May 9, 2024, to May 8, 2025 [1][3]. Company Performance - Iovance announced its financial results for Q2 of fiscal 2024 on July 25, 2024, and subsequently reduced its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance of its iCTC, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [4]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [4]. Legal Context - The class action lawsuit is on behalf of all individuals and entities that purchased Iovance securities during the specified class period, with a deadline of July 14, 2025, for investors to apply to be appointed as lead plaintiff [1]. - The lawsuit claims that the company made overwhelmingly positive statements while concealing material adverse facts about its ability to meet demand for its treatments [3]. Investor Information - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [5].

Core Viewpoint - A class action lawsuit has been filed against Strategy Incorporated (NASDAQ:MSTR) for allegedly making materially false and misleading statements regarding its business and operations during the Class Period from April 30, 2024, to April 4, 2025 [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Eastern District of Virginia on behalf of all individuals and entities who purchased or acquired Strategy securities during the specified Class Period [1]. - Investors have until July 15, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against the Company - The complaint alleges that the defendants made false and misleading statements about the anticipated profitability of the Company's bitcoin-focused investment strategy and treasury operations, which were overstated [3]. - It is claimed that the risks associated with bitcoin's volatility and potential losses on the value of digital assets were understated [3]. - As a result, the public statements made by the defendants were materially false and misleading throughout the Class Period [3]. Investor Information - Investors who suffered losses, are long-term stockholders, or have information related to the claims are encouraged to contact the law firm for more details [4].